STOCK TITAN

[Form 4] AdaptHealth Corp. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing for AdaptHealth Corp. (AHCO) reports that director David S. Williams III acquired 21,346 shares of common stock on 06/26/2025 at a stated price of $0.00 per share, suggesting the shares were received through an equity award or similar non-cash grant. Following the transaction, Williams now beneficially owns 58,245 shares, all held directly. No derivative securities or dispositions were disclosed, and the filing was signed on 06/30/2025 by an attorney-in-fact.

  • Reporting person status: Director, single filer
  • Transaction code: “A” (acquisition)
  • Ownership form: Direct
  • No sales, derivative activity, or 10b5-1 plan indicated

Deposito del Modulo 4 per AdaptHealth Corp. (AHCO) segnala che il direttore David S. Williams III ha acquisito 21.346 azioni ordinarie il 26/06/2025 ad un prezzo dichiarato di $0,00 per azione, suggerendo che le azioni sono state ricevute tramite un premio azionario o una sovvenzione simile non monetaria. Dopo la transazione, Williams possiede ora 58.245 azioni in modo beneficiario, tutte detenute direttamente. Non sono stati dichiarati titoli derivati o cessioni, e il deposito è stato firmato il 30/06/2025 da un procuratore legale.

  • Ruolo della persona che segnala: Direttore, unico dichiarante
  • Codice della transazione: “A” (acquisizione)
  • Forma di proprietà: Diretta
  • Non sono state indicate vendite, attività derivata o piani 10b5-1

Presentación del Formulario 4 para AdaptHealth Corp. (AHCO) informa que el director David S. Williams III adquirió 21,346 acciones ordinarias el 26/06/2025 a un precio declarado de $0.00 por acción, lo que sugiere que las acciones fueron recibidas mediante una concesión de capital o una subvención similar no monetaria. Tras la transacción, Williams posee ahora 58,245 acciones en propiedad beneficiaria, todas mantenidas directamente. No se divulgaron valores derivados ni disposiciones, y la presentación fue firmada el 30/06/2025 por un apoderado legal.

  • Estado de la persona que reporta: Director, declarante único
  • Código de la transacción: “A” (adquisición)
  • Forma de propiedad: Directa
  • No se indicaron ventas, actividades derivadas ni plan 10b5-1

AdaptHealth Corp. (AHCO)의 Form 4 제출에 따르면 이사 David S. Williams III가 2025년 6월 26일에 21,346주의 보통주를 주당 $0.00의 명시된 가격으로 취득했으며, 이는 주식이 주식 보상 또는 유사한 비현금 보조금 형태로 수령되었음을 시사합니다. 거래 후 Williams는 현재 58,245주의 실질 소유권을 보유하고 있으며, 모두 직접 보유 중입니다. 파생 증권이나 처분 내역은 공개되지 않았으며, 제출 서류는 2025년 6월 30일에 법정 대리인에 의해 서명되었습니다.

  • 보고자 신분: 이사, 단독 신고자
  • 거래 코드: “A” (취득)
  • 소유 형태: 직접 소유
  • 판매, 파생 활동 또는 10b5-1 계획 없음

Dépôt du formulaire 4 pour AdaptHealth Corp. (AHCO) indique que le directeur David S. Williams III a acquis 21 346 actions ordinaires le 26/06/2025 à un prix déclaré de 0,00 $ par action, ce qui suggère que les actions ont été reçues via une attribution d'actions ou une subvention similaire non monétaire. Suite à la transaction, Williams détient désormais 58 245 actions en propriété bénéficiaire, toutes détenues directement. Aucune valeur dérivée ni cession n'ont été divulguées, et le dépôt a été signé le 30/06/2025 par un mandataire.

  • Statut de la personne déclarant : Directeur, déclarant unique
  • Code de transaction : « A » (acquisition)
  • Forme de propriété : Directe
  • Aucune vente, activité dérivée ou plan 10b5-1 indiqué

Formular 4 Einreichung für AdaptHealth Corp. (AHCO) berichtet, dass Direktor David S. Williams III am 26.06.2025 21.346 Stammaktien zu einem angegebenen Preis von $0,00 pro Aktie erworben hat, was darauf hindeutet, dass die Aktien durch eine Aktienauszeichnung oder eine ähnliche nicht-monetäre Zuwendung erhalten wurden. Nach der Transaktion besitzt Williams nun 58.245 Aktien wirtschaftlich, alle direkt gehalten. Keine Derivatwerte oder Veräußerungen wurden offengelegt, und die Einreichung wurde am 30.06.2025 von einem Bevollmächtigten unterzeichnet.

  • Status der meldenden Person: Direktor, Einzelmelder
  • Transaktionscode: „A“ (Erwerb)
  • Eigentumsform: Direkt
  • Keine Verkäufe, Derivataktivitäten oder 10b5-1-Pläne angegeben
Positive
  • Director acquired 21,346 new shares, raising direct holdings to 58,245 shares.
Negative
  • None.

Insights

TL;DR – Director received 21k new shares; small, informational impact.

The acquisition increases insider holdings but involves no cash outlay, implying an equity award rather than an open-market buy. Because the stake rises to just 58k shares, the absolute ownership remains immaterial relative to AdaptHealth’s total float. The filing does not signal operational or financial changes, so market impact is expected to be limited.

TL;DR – Routine equity grant, governance compliance maintained.

The Form 4 meets Section 16 reporting requirements within two business days. No 10b5-1 notation or group filing appears, and the power-of-attorney signature is properly disclosed. From a governance viewpoint, this is standard board compensation disclosure with no red flags.

Deposito del Modulo 4 per AdaptHealth Corp. (AHCO) segnala che il direttore David S. Williams III ha acquisito 21.346 azioni ordinarie il 26/06/2025 ad un prezzo dichiarato di $0,00 per azione, suggerendo che le azioni sono state ricevute tramite un premio azionario o una sovvenzione simile non monetaria. Dopo la transazione, Williams possiede ora 58.245 azioni in modo beneficiario, tutte detenute direttamente. Non sono stati dichiarati titoli derivati o cessioni, e il deposito è stato firmato il 30/06/2025 da un procuratore legale.

  • Ruolo della persona che segnala: Direttore, unico dichiarante
  • Codice della transazione: “A” (acquisizione)
  • Forma di proprietà: Diretta
  • Non sono state indicate vendite, attività derivata o piani 10b5-1

Presentación del Formulario 4 para AdaptHealth Corp. (AHCO) informa que el director David S. Williams III adquirió 21,346 acciones ordinarias el 26/06/2025 a un precio declarado de $0.00 por acción, lo que sugiere que las acciones fueron recibidas mediante una concesión de capital o una subvención similar no monetaria. Tras la transacción, Williams posee ahora 58,245 acciones en propiedad beneficiaria, todas mantenidas directamente. No se divulgaron valores derivados ni disposiciones, y la presentación fue firmada el 30/06/2025 por un apoderado legal.

  • Estado de la persona que reporta: Director, declarante único
  • Código de la transacción: “A” (adquisición)
  • Forma de propiedad: Directa
  • No se indicaron ventas, actividades derivadas ni plan 10b5-1

AdaptHealth Corp. (AHCO)의 Form 4 제출에 따르면 이사 David S. Williams III가 2025년 6월 26일에 21,346주의 보통주를 주당 $0.00의 명시된 가격으로 취득했으며, 이는 주식이 주식 보상 또는 유사한 비현금 보조금 형태로 수령되었음을 시사합니다. 거래 후 Williams는 현재 58,245주의 실질 소유권을 보유하고 있으며, 모두 직접 보유 중입니다. 파생 증권이나 처분 내역은 공개되지 않았으며, 제출 서류는 2025년 6월 30일에 법정 대리인에 의해 서명되었습니다.

  • 보고자 신분: 이사, 단독 신고자
  • 거래 코드: “A” (취득)
  • 소유 형태: 직접 소유
  • 판매, 파생 활동 또는 10b5-1 계획 없음

Dépôt du formulaire 4 pour AdaptHealth Corp. (AHCO) indique que le directeur David S. Williams III a acquis 21 346 actions ordinaires le 26/06/2025 à un prix déclaré de 0,00 $ par action, ce qui suggère que les actions ont été reçues via une attribution d'actions ou une subvention similaire non monétaire. Suite à la transaction, Williams détient désormais 58 245 actions en propriété bénéficiaire, toutes détenues directement. Aucune valeur dérivée ni cession n'ont été divulguées, et le dépôt a été signé le 30/06/2025 par un mandataire.

  • Statut de la personne déclarant : Directeur, déclarant unique
  • Code de transaction : « A » (acquisition)
  • Forme de propriété : Directe
  • Aucune vente, activité dérivée ou plan 10b5-1 indiqué

Formular 4 Einreichung für AdaptHealth Corp. (AHCO) berichtet, dass Direktor David S. Williams III am 26.06.2025 21.346 Stammaktien zu einem angegebenen Preis von $0,00 pro Aktie erworben hat, was darauf hindeutet, dass die Aktien durch eine Aktienauszeichnung oder eine ähnliche nicht-monetäre Zuwendung erhalten wurden. Nach der Transaktion besitzt Williams nun 58.245 Aktien wirtschaftlich, alle direkt gehalten. Keine Derivatwerte oder Veräußerungen wurden offengelegt, und die Einreichung wurde am 30.06.2025 von einem Bevollmächtigten unterzeichnet.

  • Status der meldenden Person: Direktor, Einzelmelder
  • Transaktionscode: „A“ (Erwerb)
  • Eigentumsform: Direkt
  • Keine Verkäufe, Derivataktivitäten oder 10b5-1-Pläne angegeben
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williams David Solomon III

(Last) (First) (Middle)
6272 CONDON AVE

(Street)
LOS ANGELES CA 90056

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AdaptHealth Corp. [ AHCO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/26/2025 A 21,346 A $0 58,245 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24 - Power of Attorney
/s/ Richard Rew, as attorney-in-fact for David S. Williams III 06/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many AdaptHealth (AHCO) shares did the director acquire?

The Form 4 states that David S. Williams III acquired 21,346 common shares.

What is the director’s total ownership after the transaction?

Following the award, the director beneficially owns 58,245 shares of AHCO.

Was cash paid for the shares?

No. The transaction price is reported as $0.00, indicating a non-cash equity grant.

Did the filing disclose any derivative security activity?

No derivative securities were acquired or disposed of in this filing.

Is this Form 4 tied to a 10b5-1 trading plan?

The form does not indicate that the transaction was made under a Rule 10b5-1 plan.
Adapthealth Corp

NASDAQ:AHCO

AHCO Rankings

AHCO Latest News

AHCO Latest SEC Filings

AHCO Stock Data

1.27B
108.76M
11.9%
100.92%
6.99%
Medical Devices
Services-home Health Care Services
Link
United States
CONSHOHOCKEN